A Look Before the Leap

Feb 29, 2024

February 2024 is a leap year, meaning that an extra day is tacked on to the end of the shortest month to account for the fact that the Earth’s orbit around the Sun takes approximately 365.25 days; hence a leap year, with exceptions, falls every 4 years (0.25 x 4) to keep our calendar in step with the seasons.

For EpicentRx, leap year carries a different connotation—of forward progress for lead therapies, RRx-001 (nibrozetone) and AdAPT-001, in 2024.

Currently the small molecule, RRx-001 (nibrozetone), is in an ongoing Phase 3 clinical trial called REPLATINUM for the treatment of small cell lung cancer (SCLC) and will soon begin a Phase 2b clinical trial called KEVLARx for the mitigation of severe oral mucositis in head and neck cancer as well as a Phase 1/2 clinical trial for the treatment of endometriosis, a disease responsible for chronic pelvic pain.

The lead oncolytic adenovirus, AdAPT-001, that is armed with a TGF-beta (TGF-β) trap to neutralize the overexpressed cytokine, TGF-β, is in an ongoing Phase 2 clinical trial for the treatment of sarcomas in combination with a checkpoint inhibitor and will start another Phase 2 trial called HAI MAINTENANCE for the treatment of hepatocellular carcinoma (HCC) in combination with the checkpoint inhibitor, atezolizumab, and the anti-VEGF inhibitor, bevacizumab.

Granted, these are a lot of clinical trials to manage.

Fortunately, we took the time to look before the leap.